Zacks Investment Research·Jun 26, 2026
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and MarkerIndivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Ironwood Pharmaceuticals, Inc.(IRWD)Earnings, Financials & Key Ratios
IRWD•NASDAQ
$4.47
29.8× P/E·Price updated Jul 7, 2026
AboutIronwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Show more
- Revenue$296M-15.7%
- EBITDA$121M+26.8%
- Net Income$24M+2629.2%
- EPS (Diluted)0.15+2627.3%
- Gross Margin100%+2.2%
- EBITDA Margin40.74%+50.5%
- Operating Margin40.1%+51.3%
- Net Margin8.11%+3138.7%
IRWD Price & Volume
Ironwood Pharmaceuticals, Inc. (IRWD) stock price & volume — 10-year historical chart
Loading chart...
Collaboration Accounting Masks Underlying Operational Revenue Volatility
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Moderate
Financial:Vulnerable
Cash Flow:Mixed
Primary Risk:Single-product revenue concentration
Key Thesis Takeaways
- Ironwood Pharmaceuticals presents a complex investment profile defined by extreme revenue volatility, as evidenced by the 158.9% year-over-year growth in 2026Q1 following a 47.3% contraction in 2025Q4.
- While the company maintains high gross margins near 99.6%, its reliance on a single-product collaboration model creates significant earnings instability and necessitates constant monitoring of partner-driven cash flows.
- Investors should remain cautious regarding the firm's long-term solvency, given the persistent negative equity position of $217.1 million and a substantial debt load of $597.4 million as of 2026Q1.
Verdict Logic
the company's reliance on a single-product collaboration model and its precarious balance sheet, highlighted by a negative equity position of $217.1 million, present excessive risks for long-term capital appreciation.
IRWD Growth Metrics
Ironwood Pharmaceuticals, Inc. (IRWD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years7.07%
5 Years-5.33%
3 Years-10.32%
TTM13.8%
Profit CAGR
10 Years-
5 Years-25.72%
3 Years-48.42%
TTM415.9%
EPS CAGR
10 Years-
5 Years-25.65%
3 Years-46.14%
TTM400.86%
Return on Capital
10 Years-1.74%
5 Years-1.12%
3 Years-20.42%
Last Year50.89%
IRWD Recent Earnings
Ironwood Pharmaceuticals, Inc. (IRWD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.24+242.9%
$0.07
Rev
$107M+15.6%
$92M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.01-150.0%
$0.02
Rev
$48M-6.3%
$51M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.24+166.7%
$0.09
Rev
$122M+139.6%
$51M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.14+800.0%
$0.02
Rev
$85M+9.5%
$78M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.24vs $0.07+242.9% | $107Mvs $92M+15.6% |
| Q1 2026 | Feb 25, 2026 | $0.01vs $0.02-150.0% | $48Mvs $51M-6.3% |
| Q4 2025 | Nov 10, 2025 | $0.24vs $0.09+166.7% | $122Mvs $51M+139.6% |
| Q3 2025 | Aug 7, 2025 | $0.14vs $0.02+800.0% | $85Mvs $78M+9.5% |
Based on last 12 quarters of dataView full earnings history →
Latest IRWD News
Recent stock market news and headlines for Ironwood Pharmaceuticals, Inc. (IRWD)
Zacks Investment Research·Jun 25, 2026
5 Small Drug Stocks to Invest in Amid a Biotech ComebackInnovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Peers Comparison
Key metrics vs top competitors for Ironwood Pharmaceuticals, Inc. (IRWD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.47 | $735.82M | 29.80 | -15.72% | 8.11% | — | — | |
| $140.85 | $9.06B | -68.71 | -89.41% | -648.27% | -17.76% | — | |
| $5.38 | $1.32B | -20.69 | 22.09% | -13.58% | -38.11% | — | |
| $6.29 | $94.24M | -33.11 | 17.57% | -17.24% | -29.12% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $11.19 | $1.55B | -1.09 | -2.75% | -43.5% | -50.65% | — |
Compare IRWD vs Peers
Ironwood Pharmaceuticals, Inc. (IRWD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IRWD SEC Filings & Documents
Ironwood Pharmaceuticals, Inc. (IRWD) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Mar 11, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when IRWD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IRWD Frequently Asked Questions
Ironwood Pharmaceuticals, Inc. (IRWD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Ironwood Pharmaceuticals, Inc.'s revenue?
Ironwood Pharmaceuticals, Inc. (IRWD) reported $361.5M in revenue for fiscal year 2025. This represents a 3355% increase from $10.5M in 2007.
How fast is Ironwood Pharmaceuticals, Inc. growing?
Ironwood Pharmaceuticals, Inc. (IRWD) saw revenue decline by 15.7% over the past year.
Is IRWD profitable?
Yes, Ironwood Pharmaceuticals, Inc. (IRWD) is profitable, generating $102.2M in net income for fiscal year 2025 (8.1% net margin).
Dividend & Returns
What is Ironwood Pharmaceuticals, Inc.'s free cash flow?
Ironwood Pharmaceuticals, Inc. (IRWD) generated $112.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.